Safety of Different Doses of Ulinastatin Combined with Remifentanilin the Treatment of Severe Sepsis in ICU and Their effect on Survival Rate and Organ Function of Patients

Abstract

The purpose was to explore the safety of different doses of ulinastatin combined with remifentanilin the treatment of severe sepsis in ICUand to analyze their effect on survival rate and organ function of patients. Methods. 57 patients with severe sepsis in ICU admitted to our hospital (2018.1.1-2021.6.30) were selected as the research subjects, and randomly divided into control group (28 cases) and experimental group (29 cases). The control group was treated with conventional dose of ulinastatin combined with remifentanil, while the experimental group was treated with high dose of ulinastatin combined with remifentanil to compare and analyze the treatment safety, organ function and survival rate in the two groups.Results. After treatment, the APACHE-II scores of both groups were lower than those before treatment, and the APACHE-II score in the experimental group was lower than that in the control group (P < 0.05). There were statistically significant differences in ventilator supporting time and ICU stay time between the two groups after treatment (P < 0.05). The expression levels of inflammatory factors in the experimental group were lower than those in the control group after treatment (P < 0.05). The lung function and PICCO indexes in the experimental group were better than those in the control group after treatment (P < 0.05). The peripheral blood CD4⁺, CD8⁺, CD4⁺/CD8⁺ and 28-day survival rate in the experimental group were higher than those in the control group (P < 0.05). No adverse drug reactions such as sudden vomiting, dyspnea and rash occurred in the two groups during the treatment. Conclusion. High-dose ulinastatin combined with remifentanilhas good therapeutic effect on severe sepsis in ICU. Compared with conventional dose, high-dose ulinastatin can effectively protect the body’s immune regulation, restore organ function and significantly improve the 28-day survival rate of patients, with medicationsafety, which has high value of clinical application and promotion.